---
title: "Klotho Neurosciences - W27 | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265783815.md"
datetime: "2025-11-13T20:16:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265783815.md)
  - [en](https://longbridge.com/en/news/265783815.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265783815.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265783815.md) | [繁體中文](https://longbridge.com/zh-HK/news/265783815.md)


# Klotho Neurosciences - W27 | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.05.

EBIT: As of FY2025 Q3, the actual value is USD -675.31 K.

### Segment Revenue

-   The company did not generate any revenue for the three and nine months ended September 30, 2025, and 2024.

### Operational Metrics

-   **Net Loss**: For the three months ended September 30, 2025, the net loss was $2,895,585 compared to $2,959,426 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $9,222,798 compared to $4,083,109 for the same period in 2024.
-   **Operating Expenses**: For the three months ended September 30, 2025, operating expenses were $1,853,304 compared to $2,870,932 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $5,333,124 compared to $3,688,584 for the same period in 2024.
-   **Interest Expense**: For the three months ended September 30, 2025, interest expense was $1,177,999 compared to $44,956 for the same period in 2024. For the nine months ended September 30, 2025, interest expense was $3,491,961 compared to $60,020 for the same period in 2024.
-   **Share-based Compensation**: For the three months ended September 30, 2025, share-based compensation was $639,586 compared to $1,952,852 for the same period in 2024. For the nine months ended September 30, 2025, share-based compensation was $1,525,281 compared to $1,990,366 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was $4,610,390 compared to $2,002,358 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: For the nine months ended September 30, 2025, net cash used in investing activities was $0 compared to $123,497 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the nine months ended September 30, 2025, net cash provided by financing activities was $11,894,683 compared to $2,173,942 for the same period in 2024.

### Unique Metrics

-   **Licenses and Patents**: The company acquired various licenses and patents, including a Non-Exclusive License Agreement, various generic drugs, four generic drugs (Encore), and a Needleless Syringe License. The total value of intangible assets as of September 30, 2025, was $2,299,554.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue developing essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform, as well as two proprietary, patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform.
-   **Non-Core Business**: The company terminated the Share Exchange Agreement to acquire SB Security Holdings, LLC, an internet-connected video doorbell service company, on June 13, 2025.
-   **Priority**: The company is focused on obtaining additional working capital funding from the sale of equity and/or debt securities to continue executing its development plans and operations. Without additional funding, there is substantial doubt about the company’s ability to continue as a going concern for twelve months from the date of these financial statements.

### Related Stocks

- [Klotho Neurosciences - W27 (KLTOW.US)](https://longbridge.com/en/quote/KLTOW.US.md)
- [GREENLAND MINES LTD C/WTS 21/06/2029 (TO PUR COM) (GRMLW.US)](https://longbridge.com/en/quote/GRMLW.US.md)

## Related News & Research

- [Rudrabhishek Enterprises Clears Q3 FY26 Results, Names New Compliance Chief](https://longbridge.com/en/news/278863408.md)
- [Casey's Q3 net income surges, partly on strong grocery sales](https://longbridge.com/en/news/278444882.md)
- [Exchange Seeks Clarification From STC India on Q3 FY2025 Results](https://longbridge.com/en/news/278683960.md)
- [Barnes & Noble Education Q3 revenue rises](https://longbridge.com/en/news/278611372.md)
- [Heritage Insurance Hldgs: Q4 Earnings Insights](https://longbridge.com/en/news/278374826.md)